
WHAT IS CLAIMED IS:

1. A pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, comprising cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.

2. The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, according to Claim 1, characterized in that the cromolyn is a compound represented by [Formula 1] below:

[Formula 1]



3. The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, according to Claim 1, characterized in that the cromolyn inhibits the accumulation of collagen in hepatic stellate cell (HSC).

4. The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, according to Claim 1, characterized in that the cromolyn inhibits the production of TGF-β in hepatic stellate cell.

5. The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, according to Claim 1, characterized in that the cromolyn inhibits the decrease in expression of E-cadherin in hepatocyte.

6. The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, according to Claim 1, characterized in that the cromolyn has anti-senescence activity on hepatocytes.

7. A health food for preventing and ameliorating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, comprising cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.

8. The health food for preventing and ameliorating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, according to Claim 7, characterized in that the cromolyn inhibits the activity of hepatic stellate cell and recovers a hepatocyte function.